{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:00:27Z","timestamp":1785891627191,"version":"3.56.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019120","name":"Otsuka America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jtocrr.2022.100278","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T12:20:47Z","timestamp":1642681247000},"page":"100278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs"],"prefix":"10.1016","volume":"3","author":[{"given":"Roberta","family":"Minari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cavazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"La Monica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza Anna Maria","family":"Lagrasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bertorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"De Sanctis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Azzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Bottarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Frati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Gnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Facchinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Giorgio","family":"Petronini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Romanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2022.100278_bib1","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","article-title":"Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer","volume":"36","author":"Solomon","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2022.100278_bib2","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.21037\/tlcr-20-372","article-title":"Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won","volume":"9","author":"Tabb\u00f2","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtocrr.2022.100278_bib3","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtocrr.2022.100278_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.tranon.2018.09.013","article-title":"MYC amplification as a potential mechanism of primary resistance to crizotinib in ALK-rearranged non-small cell lung cancer: a brief report","volume":"12","author":"Rihawi","year":"2019","journal-title":"Transl Oncol"},{"key":"10.1016\/j.jtocrr.2022.100278_bib5","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1164\/rccm.201807-1292OC","article-title":"YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib","volume":"200","author":"Garmendia","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtocrr.2022.100278_bib6","doi-asserted-by":"crossref","first-page":"E6030","DOI":"10.1073\/pnas.1717782115","article-title":"YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics","volume":"115","author":"Fan","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl 15","key":"10.1016\/j.jtocrr.2022.100278_bib7","article-title":"YES1 amplification as a primary driver of lung tumorigenesis and YES1\/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs)","volume":"38","author":"Sato","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2022.100278_bib8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-14-0552","article-title":"Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map","volume":"5","author":"Martins","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtocrr.2022.100278_bib9","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1158\/0008-5472.CAN-18-3376","article-title":"YES1 is a targetable oncogene in cancers harboring YES1 gene amplification","volume":"79","author":"Hamanaka","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2022.100278_bib10","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910581","article-title":"Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer","volume":"11","author":"Yun","year":"2019","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jtocrr.2022.100278_bib11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41467-019-13771-5","article-title":"YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation","volume":"11","author":"Tsuji","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtocrr.2022.100278_bib12","first-page":"599","article-title":"SOX9 promotes epithelial-mesenchymal transition via the Hippo-YAP signaling pathway in gastric carcinoma cells","volume":"18","author":"Zhou","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jtocrr.2022.100278_bib13","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.yexcr.2016.11.024","article-title":"Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer","volume":"350","author":"Ling","year":"2017","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jtocrr.2022.100278_bib14","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.celrep.2016.11.022","article-title":"Genomic instability is induced by persistent proliferation of cells undergoing epithelial-to-mesenchymal transition","volume":"17","author":"Comaills","year":"2016","journal-title":"Cell Rep"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364322000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364322000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:37:39Z","timestamp":1762987059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364322000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2666364322000030"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100278","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100278"}}